Make DrugFinder Application
Apply to the InhibOx/NFCR
virtual screening service


DeZnIT Go to DeZnIT website
The website of our FP6 consortium.

MolPort
InhibOx works closely with
MolPort, a one-stop shop for
compound acquisition.

Welcome to InhibOx

InhibOx develops novel and effective computational methods for drug discovery, to improve the productivity of lead and candidate identification.

InhibOx was founded in 2001 by Professor W. Graham Richards, former Chairman of Chemistry at the University of Oxford and world leading computational chemist. The company grew from the outstandingly successful Screensaver Lifesaver project which involved some 3.5 million personal computers in over 200 countries: the world's biggest computational chemistry experiment finding lead compounds to inhibit cancer targets, anthrax and smallpox.

Since then, InhibOx has built up a significant technology platform in virtual screening. Our ongoing research activities comprise the development of entirely novel computational drug discovery methods and the development of Scopius and CSpace, a very large and carefully curated database of commercially-available chemical structures.

DrugFinder

DrugFinder is our virtual screening web service that searches millions of commercially-available molecules against a target protein structure you supply—and it's free to academics. more...





“InhibOx has helped redesign the company’s drug targeting programme, and suggested new lines of derivitization that have delivered compounds with the properties we wanted. The competence InhibOx provides and the quality of what they deliver is exceptional.”

Kjetil Tasken, Lauras VP R&D

News

February, 2010

Intelligensys and InhibOx Apply Proven Formulation Approaches to Improve Lead Discovery Efficiency more...

December, 2009

InhibOx and Molport Join Forces to Deliver Integrated Lead Design and Delivery more...

November, 2009

InhibOx announces important breakthrough in molecular similarity: Chiral Shape Recognition (CSR) more...

Successful DrugFinder collaboration with Oxford University Chemistry Department discovers novel kinase inhibitors. more...

September, 2009

Prof. W. Graham Richards discusses his latest book, “Spin-Outs” more...

InhibOx presents at 8th International Symposium on Carbonic Anhydrases: “Computational Approaches to the Design of New Carbonic Anhdydrase Inhibitors”. more...

InhibOx presents at ELRIG Drug Discovery 2009: “Harnessing Modern Web Technologies for Virtual Screening”. more...

August, 2009

InhibOx appoints Paul Davie to lead Commercial Growth. more...

InhibOx collaborates with Lauras AS to advance its drug discovery projects. more...

Older news...